2024 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium

San Francisco, California, US 18 January 2024 - 20 January 2024

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

05 Mar 2024 by

Adding lutetium-177 (¹⁷⁷Lu)–Dotatate radioligand therapy (RLT) to long-acting octreotide as first-line therapy significantly improves progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor-positive (SSTR+), grade 2 and 3 (G2 and G3), well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs) compared with high-dose long-acting octreotide alone, according to the NETTER-2 trial presented at ASCO GI 2024.

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

05 Mar 2024

Durvalumab plus chemo for GC/GEJC delivers globally consistent benefit

25 Feb 2024 by

Combination treatment with durvalumab plus FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) leads to higher rates of pathologic complete response (pCR) in patients with resectable gastric cancer (GC) or gastroesophageal junction cancer (GEJC), with the benefit universally observed regardless of geographic location, according to the subgroup analysis of the phase III MATTERHORN study.

Durvalumab plus chemo for GC/GEJC delivers globally consistent benefit

25 Feb 2024

Pembrolizumab delivers long-term survival benefits in advanced esophageal cancer

24 Feb 2024 by

First-line pembrolizumab (pembro) plus chemotherapy (chemo) in patients with untreated advanced esophageal cancer demonstrates robust efficacy after 5 years, with no new safety concerns, when compared with placebo plus chemo, according to a study presented at ASCO GI 2024.

Pembrolizumab delivers long-term survival benefits in advanced esophageal cancer

24 Feb 2024

Thoracoscopic esophagectomy better than open surgery in esophageal cancer

23 Feb 2024 by

Thoracoscopic esophagectomy (TE) has demonstrated its noninferiority to open transthoracic esophagectomy (OE) for patients with thoracic esophageal cancer in a study presented at ASCO GI 2024.

Thoracoscopic esophagectomy better than open surgery in esophageal cancer

23 Feb 2024

SKYSCRAPER-08 hits mark in ESCC with dual checkpoint inhibition + doublet chemo

16 Feb 2024 by

In Asian patients with esophageal squamous cell carcinoma (ESCC), adding the TIGIT inhibitor tiragolumab and PD-L1 inhibitor atezolizumab to chemotherapy improved all outcomes in the phase III SKYSCRAPER-08 trial.

SKYSCRAPER-08 hits mark in ESCC with dual checkpoint inhibition + doublet chemo

16 Feb 2024

Immunotherapy, TACE-based regimen may reshape HCC treatment landscape

13 Feb 2024 by

In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.

Immunotherapy, TACE-based regimen may reshape HCC treatment landscape

13 Feb 2024

Nivolumab-ipilimumab improves PFS in MSI-H/dMMR metastatic CRC

02 Feb 2024 by

In the first-line treatment of patients with microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (CRC), dual immunotherapy using a combination of nivolumab and ipilimumab delivers a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy, according to the CheckMate 8HW trial presented at ASCO GI 2024.

Nivolumab-ipilimumab improves PFS in MSI-H/dMMR metastatic CRC

02 Feb 2024